Spain · Delayed Price · Currency is EUR Pharma Mar Statistics
Total Valuation
Pharma Mar has a market cap or net worth of EUR 1.45 billion. The enterprise value is 1.33 billion.
| Market Cap | 1.45B |
| Enterprise Value | 1.33B |
Important Dates
The last earnings date was Thursday, July 30, 2026.
| Earnings Date | Jul 30, 2026 |
| Ex-Dividend Date | Jul 8, 2026 |
Share Statistics
Pharma Mar has 17.34 million shares outstanding. The number of shares has increased by 3.57% in one year.
| Current Share Class | 17.34M |
| Shares Outstanding | 17.34M |
| Shares Change (YoY) | +3.57% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 12.06% |
| Owned by Institutions (%) | 10.87% |
| Float | 13.40M |
Valuation Ratios
The trailing PE ratio is 26.86 and the forward PE ratio is 20.24. Pharma Mar's PEG ratio is 0.96.
| PE Ratio | 26.86 |
| Forward PE | 20.24 |
| PS Ratio | 6.63 |
| PB Ratio | 5.78 |
| P/TBV Ratio | 5.87 |
| P/FCF Ratio | 26.83 |
| P/OCF Ratio | 23.30 |
| PEG Ratio | 0.96 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 28.38, with an EV/FCF ratio of 24.55.
| EV / Earnings | 23.63 |
| EV / Sales | 6.07 |
| EV / EBITDA | 28.38 |
| EV / EBIT | 34.12 |
| EV / FCF | 24.55 |
Financial Position
The company has a current ratio of 2.85, with a Debt / Equity ratio of 0.18.
| Current Ratio | 2.85 |
| Quick Ratio | 2.20 |
| Debt / Equity | 0.18 |
| Debt / EBITDA | 0.98 |
| Debt / FCF | 0.85 |
| Interest Coverage | 46.21 |
Financial Efficiency
Return on equity (ROE) is 24.82% and return on invested capital (ROIC) is 30.24%.
| Return on Equity (ROE) | 24.82% |
| Return on Assets (ROA) | 6.55% |
| Return on Invested Capital (ROIC) | 30.24% |
| Return on Capital Employed (ROCE) | 13.17% |
| Weighted Average Cost of Capital (WACC) | 6.44% |
| Revenue Per Employee | 432,958 |
| Profits Per Employee | 111,141 |
| Employee Count | 505 |
| Asset Turnover | 0.59 |
| Inventory Turnover | 0.29 |
Taxes
| Income Tax | -15.32M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +3.83% in the last 52 weeks. The beta is 0.43, so Pharma Mar's price volatility has been lower than the market average.
| Beta (5Y) | 0.43 |
| 52-Week Price Change | +3.83% |
| 50-Day Moving Average | 78.73 |
| 200-Day Moving Average | 82.69 |
| Relative Strength Index (RSI) | 60.05 |
| Average Volume (20 Days) | 37,534 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Pharma Mar had revenue of EUR 218.64 million and earned 56.13 million in profits. Earnings per share was 3.11.
| Revenue | 218.64M |
| Gross Profit | 204.17M |
| Operating Income | 38.87M |
| Pretax Income | 40.81M |
| Net Income | 56.13M |
| EBITDA | 44.83M |
| EBIT | 38.87M |
| Earnings Per Share (EPS) | 3.11 |
Balance Sheet
The company has 168.88 million in cash and 45.84 million in debt, with a net cash position of 123.04 million or 7.10 per share.
| Cash & Cash Equivalents | 168.88M |
| Total Debt | 45.84M |
| Net Cash | 123.04M |
| Net Cash Per Share | 7.10 |
| Equity (Book Value) | 250.78M |
| Book Value Per Share | 14.47 |
| Working Capital | 182.53M |
Cash Flow
In the last 12 months, operating cash flow was 62.21 million and capital expenditures -8.19 million, giving a free cash flow of 54.02 million.
| Operating Cash Flow | 62.21M |
| Capital Expenditures | -8.19M |
| Depreciation & Amortization | 5.96M |
| Net Borrowing | -8.66M |
| Free Cash Flow | 54.02M |
| FCF Per Share | 3.12 |
Margins
Gross margin is 93.38%, with operating and profit margins of 17.78% and 25.67%.
| Gross Margin | 93.38% |
| Operating Margin | 17.78% |
| Pretax Margin | 18.66% |
| Profit Margin | 25.67% |
| EBITDA Margin | 20.50% |
| EBIT Margin | 17.78% |
| FCF Margin | 24.71% |
Dividends & Yields
This stock pays an annual dividend of 1.00, which amounts to a dividend yield of 1.22%.
| Dividend Per Share | 1.00 |
| Dividend Yield | 1.22% |
| Dividend Growth (YoY) | 25.00% |
| Years of Dividend Growth | 2 |
| Payout Ratio | n/a |
| Buyback Yield | -3.57% |
| Shareholder Yield | -2.35% |
| Earnings Yield | 3.87% |
| FCF Yield | 3.73% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for Pharma Mar is 104.39, which is 24.87% higher than the current price. The consensus rating is "Buy".
| Price Target | 104.39 |
| Price Target Difference | 24.87% |
| Analyst Consensus | Buy |
| Analyst Count | 9 |
| Revenue Growth Forecast (3Y) | 19.72% |
| EPS Growth Forecast (3Y) | 31.81% |
Stock Splits
The last stock split was on July 22, 2020. It was a reverse split with a ratio of 0.0833333333.
| Last Split Date | Jul 22, 2020 |
| Split Type | Reverse |
| Split Ratio | 0.0833333333 |
Scores
Pharma Mar has an Altman Z-Score of 8.32 and a Piotroski F-Score of 7.
| Altman Z-Score | 8.32 |
| Piotroski F-Score | 7 |